share_log

We Ran A Stock Scan For Earnings Growth And Chengdu Kanghong Pharmaceutical Group (SZSE:002773) Passed With Ease

We Ran A Stock Scan For Earnings Growth And Chengdu Kanghong Pharmaceutical Group (SZSE:002773) Passed With Ease

我們對盈利增長進行了股票篩選,康弘藥業 (SZSE:002773) 輕鬆通過。
Simply Wall St ·  12/12 17:33

It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story even if these companies are loss-making. But as Peter Lynch said in One Up On Wall Street, 'Long shots almost never pay off.' While a well funded company may sustain losses for years, it will need to generate a profit eventually, or else investors will move on and the company will wither away.

許多投資者,特別是那些缺乏經驗的投資者,常常購買那些即使虧損但有好故事的公司的股票。但正如彼得·林奇在《華爾街之狼》中所說,'長期投資幾乎從來不會帶來回報。'雖然一家公司可以在多年內持續虧損,但最終它需要實現盈利,否則投資者將會轉向其他公司,企業也將隨之消亡。

So if this idea of high risk and high reward doesn't suit, you might be more interested in profitable, growing companies, like Chengdu Kanghong Pharmaceutical Group (SZSE:002773). While profit isn't the sole metric that should be considered when investing, it's worth recognising businesses that can consistently produce it.

因此,如果這種高風險高回報的想法不適合你,那麼你可能會對盈利且持續增長的公司更感興趣,比如康弘藥業(SZSE:002773)。雖然盈利不是投資時應考慮的唯一指標,但值得關注能夠持續產生利潤的企業。

How Fast Is Chengdu Kanghong Pharmaceutical Group Growing?

康弘藥業的增長速度有多快?

The market is a voting machine in the short term, but a weighing machine in the long term, so you'd expect share price to follow earnings per share (EPS) outcomes eventually. Therefore, there are plenty of investors who like to buy shares in companies that are growing EPS. To the delight of shareholders, Chengdu Kanghong Pharmaceutical Group has achieved impressive annual EPS growth of 48%, compound, over the last three years. While that sort of growth rate isn't sustainable for long, it certainly catches the eye of prospective investors.

市場在短期內是投票機,但在長期內是稱重機,因此你會期待股價最終跟隨每股收益(EPS)結果。因此,有很多投資者喜歡購買每股收益正在增長的公司的股票。讓股東欣喜的是,康弘藥業在過去三年中實現了48%的年度每股收益複合增長。雖然這種增長率無法長期維持,但它肯定吸引了潛在投資者的注意。

Careful consideration of revenue growth and earnings before interest and taxation (EBIT) margins can help inform a view on the sustainability of the recent profit growth. Chengdu Kanghong Pharmaceutical Group shareholders can take confidence from the fact that EBIT margins are up from 26% to 29%, and revenue is growing. That's great to see, on both counts.

仔細考慮營業收入增長和利息與稅前利潤(EBIT)利潤率可以幫助我們對近期利潤增長的可持續性形成看法。康弘藥業的股東可以相信EBIT利潤率已從26%上升至29%,且營業收入在增長。在這兩方面看到這些數據真的很好。

The chart below shows how the company's bottom and top lines have progressed over time. Click on the chart to see the exact numbers.

下面的圖表顯示了公司的底線和頂線隨時間的發展情況。單擊圖表以查看確切的數字。

big
SZSE:002773 Earnings and Revenue History December 12th 2024
SZSE:002773 每股收益和營業收入歷史 2024年12月12日

While profitability drives the upside, prudent investors always check the balance sheet, too.

盈利能力推動上漲,但謹慎的投資者也總是檢查資產負債表。

Are Chengdu Kanghong Pharmaceutical Group Insiders Aligned With All Shareholders?

康弘藥業的內部人士是否與所有板塊的股東保持一致?

Theory would suggest that it's an encouraging sign to see high insider ownership of a company, since it ties company performance directly to the financial success of its management. So we're pleased to report that Chengdu Kanghong Pharmaceutical Group insiders own a meaningful share of the business. Actually, with 39% of the company to their names, insiders are profoundly invested in the business. This should be a welcoming sign for investors because it suggests that the people making the decisions are also impacted by their choices. This is an incredible endorsement from them.

理論上,高內部持股比例是一個好的跡象,因爲這將公司的表現與管理層的財務成功直接關聯起來。所以我們很高興地報告,康弘藥業的內部人士擁有公司相當可觀的股份。實際上,內部人士持有該公司39%的股份,深度投資於業務。這對投資者來說應該是一個良好的信號,因爲這表明做出決策的人也受到他們選擇的影響。這是他們對公司的一個不可思議的認可。

Does Chengdu Kanghong Pharmaceutical Group Deserve A Spot On Your Watchlist?

康弘藥業是否值得列入您的自選?

Chengdu Kanghong Pharmaceutical Group's earnings per share have been soaring, with growth rates sky high. This level of EPS growth does wonders for attracting investment, and the large insider investment in the company is just the cherry on top. At times fast EPS growth is a sign the business has reached an inflection point, so there's a potential opportunity to be had here. Based on the sum of its parts, we definitely think its worth watching Chengdu Kanghong Pharmaceutical Group very closely. Even so, be aware that Chengdu Kanghong Pharmaceutical Group is showing 1 warning sign in our investment analysis , you should know about...

康弘藥業的每股收益正在飆升,增長率極高。這種EPS增長水平對吸引投資大有裨益,而且公司內部的巨大投資更是錦上添花。有時,快速的EPS增長是公司達到了轉折點的標誌,因此這裏可能存在機會。根據整體來看,我們絕對認爲值得密切關注康弘藥業。儘管如此,請注意,康弘藥業在我們的投資分析中顯示出一個警示信號,您應該了解...

Although Chengdu Kanghong Pharmaceutical Group certainly looks good, it may appeal to more investors if insiders were buying up shares. If you like to see companies with more skin in the game, then check out this handpicked selection of Chinese companies that not only boast of strong growth but have strong insider backing.

儘管康弘藥業看起來很好,但如果內部人士購買股票,可能會吸引更多投資者。如果你喜歡看到那些更有投入的公司,那麼請查看這份精心挑選的中國公司名單,這些公司不僅擁有強勁的增長,而且有強大的內部支持。

Please note the insider transactions discussed in this article refer to reportable transactions in the relevant jurisdiction.

請注意,本文討論的內部交易是指在相關管轄區內可報告的交易。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對本文有反饋?對內容有疑慮?請直接與我們聯繫。或者,發送電子郵件至 editorial-team (at) simplywallst.com。
這篇來自Simply Wall St的文章是一般性的。我們根據歷史數據和分析師預測提供評論,採用無偏見的方法,我們的文章並不旨在提供財務建議。它不構成對任何股票的買入或賣出建議,也未考慮到您的目標或財務狀況。我們旨在爲您提供以基本數據驅動的長期分析。請注意,我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall St在提到的任何股票中均沒有持倉。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論